Breaking News
Get 50% Off 0
🚀 June’s AI-picked stocks soar, with Adobe +18.1% in 11 days. Don’t miss July’s upcoming picks. Unlock full list
Close

GT Biopharma Inc (GTBP)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow GT Biopharma's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
2.990 +0.070    +2.40%
18/06 - Closed. Currency in USD ( Disclaimer )
After Hours
2.960
-0.030
-1.003%
19:48:54 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 48,014
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 2.870 - 3.161
GT Biopharma 2.990 +0.070 +2.40%

GT Biopharma Inc Company Profile

 
Get an in-depth profile of GT Biopharma Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

-

Equity Type

ORD

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 (GTB-3550) TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.

Contact Information

Address 8000 Marina Boulevard Suite 100
Brisbane, 94005
United States
Phone 415 919 4040
Fax -

Top Executives

Name Age Since Title
Bruce Wendel 68 2020 Independent Vice Chairman
Michael Martin Breen 59 2021 Interim CEO & Executive Chairman
Philip G. Werthman - 2020 Chairman of Science Advisory Board
Jeffrey S. Miller - 2017 Consulting Chief Scientific Officer, Consulting Chief Medical Officer & Scientific Advisor
Arjun V. Balar - 2021 Member of Scientific Advisory Board
Samir Taneja - 2020 Member of Scientific & Medical Advisory Board
Lisa A. Haile - - Scientific Advisor
Charles J. Casamento 78 2023 Independent Director
Rajesh C. Shrotriya 79 2021 Independent Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

GTBP Comments

Write your thoughts about GT Biopharma Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Giuseppe Giannachi
Giuseppe Giannachi May 20, 2024 12:09PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Holy...
Andrew Dardi
Andrew Dardi Dec 30, 2021 8:01AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Pipeline of this company is terrific, one of the most promising on the board. Average one year target price according to qualified analysts panel is 25 USD (Bloomberg). Market is ignoring all this evidence. To me looks alike a strong buy down here.
Saintclar Cédric
Saintclar Cédric Dec 30, 2020 2:36PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
wait for nasdaq....or phase 1....well
Vinc Co
Vinc Co Dec 03, 2020 11:06AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Any thought on this
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email